Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

29. August 2018 07:00 ET | Quelle: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals to Participate in Two Healthcare Investor Conferences in September

HOUSTON, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
07. August 2018 16:05 ET | Quelle: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Reports Second Quarter 2018 Financial Results

HOUSTON, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
06. August 2018 07:00 ET | Quelle: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Appoints Dr. Thierry Darcis as General Manager of Europe to Lead the Anticipated Launch of BPX-501

HOUSTON, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
31. Juli 2018 07:00 ET | Quelle: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 7, 2018

HOUSTON, July 31, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
16. Juli 2018 16:25 ET | Quelle: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Announces Departure of Chief Financial Officer

HOUSTON, July 16, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
30. Mai 2018 07:00 ET | Quelle: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference

HOUSTON, May 30, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
29. Mai 2018 07:00 ET | Quelle: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Appoints Shane Ward as General Counsel

HOUSTON, May 29, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
17. Mai 2018 09:20 ET | Quelle: Bellicum Pharmaceuticals, Inc.

Bellicum Announces Clinical Presentations on Lead Product Candidate BPX-501 at the 23rd Congress of the European Hematology Association

HOUSTON, May 17, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
15. Mai 2018 07:00 ET | Quelle: Bellicum Pharmaceuticals, Inc.

Bellicum Announces Oral Presentation on Dual-Switch CAR-T Technology at the 21st Annual Meeting of the American Society of Gene and Cell Therapy

HOUSTON, May 15, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
08. Mai 2018 16:01 ET | Quelle: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Reports First Quarter 2018 Financial Results

HOUSTON, May 08, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...

Vorherige Seite

Nächste Seite